Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.…
Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial
Neuphoria Therapeutics (NASDAQ: NEUP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1 employees.
The shares were at 2.350 USD on 20 November 2026, down 42.7% over 52 weeks. Its 52-week range is 2.260 USD to 5.530 USD: the price is 57.5% below the high and 4.0% above the low.
Its market capitalisation is 12.72M USD.
Neuphoria Therapeutics reports return on equity of -54.7% and an operating margin of -475.6%.
It holds more cash than debt, a net cash position of 18.74M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.